30 MR tomographies were performed in 15 @entity1 suspected of having a @entity2013 on account of clinical examinations and test in the chemical laboratory. The T1 and T2 times of the @entity652 were determined quantitatively. In addition, high resolution CT imaging had been performed in all @entity1 . The signal performance of the normal pituitary gland determined in 11 healthy @entity1 on the basis of quantitatively measured T1 and T2 times, was found to largely correspond with that of grey matter of the brain. Of the 14 confirmed @entity2013 , 11 were microadenomas and 3 macroadenoma. Solid @entity652 were identified by enhanced T1 values. It was possible to differentiate these from cystic, @entity548 and @entity5 components by differences in signal performance. 7 @entity1 on drug therapy with @entity935 agonists were controlled by means of MR tomography. No measurable size reduction of @entity5 was seen in 3 @entity1 with cystic or @entity548 @entity5 components. On the other hand, @entity5 reduction was seen after brief drug therapy in 2 @entity2013 and one @entity2013 . An essential advantage offered by MR is, besides the absence of exposure to radiation, in the first place the better and more precise information on the relative position of the @entity652 with reference to the vessels and the optic chiasm, and, secondly, better identification of cystic and @entity548 processes within the @entity2013 .

[Value of nuclear magnetic resonance tomography in the diagnosis and therapy outcome of XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'persons'] @entity2013 :: ('MESH:D015175', 'Disease') :: ['prolactinoma', 'macroprolactinomas', 'prolactinomas', 'microprolactinoma'] @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhagic'] @entity5 :: ('MESH:D009369', 'Disease') :: ['necrotic tumour', 'tumour'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'adenoma']
@entity2013 :: (MESH:D015175,Disease) :: ['prolactinomas']
